AI assistant
ATOMO DIAGNOSTICS LIMITED — Investor Presentation 2025
Apr 22, 2025
64440_rns_2025-04-22_5a41c6c5-f7fc-4225-a0d5-12d67235dc56.pdf
Investor Presentation
Open in viewerOpens in your device viewer
23 April 2025
==> picture [75 x 73] intentionally omitted <==
ASX Announcement
Atomo Investor Webinar Presentation
SYDNEY Australia, 23 April 2025 –Atomo Diagnostics Limited (ASX: AT1 ) ( Atomo or the Company ) will release its Q3 FY25 Results on Thursday 24[th] April 2025.
A results briefing webinar for analysts and investors, hosted by Managing Director & CEO, John Kelly will be held on Wednesday 30[th] April 2025 at 2pm (AEST).
To access the webinar please pre-register by clicking this link.
Please submit any questions in advance of the webinar commencing to: [email protected]
~ ENDS ~
For more information, please contact:
John Kelly Investor Queries Managing Director & CEO [email protected] e. [email protected] p. +61 401 922 279
This announcement was authorised by the Managing Director & CEO on behalf of the Board.
About Atomo
Atomo is an Australian-headquartered medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market.
Atomo’s unique patented devices simplify testing procedures, enhance usability and improve reliability across rapid point-of-care (POC) and at-home testing applications. The Company has successfully commercialised a number of products across international markets and has supply agreements in place for testing applications targeting infectious diseases including COVID-19, HIV, viral vs bacterial differentiation and female health. See more at www.atomodiagnostics.com
Level 1, 3-5 George St Leichhardt NSW 2040
Atomo Diagnostics Limited ACN 142 925 684